You are here

Article Text

Article menu
Download PDFPDF
News
EU news
EMA/HMA joint statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU
  1. Stephanie Kohl
  1. Policy & Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium
  1. Correspondence to Stephanie Kohl, Policy & Advocacy, European Association of Hospital Pharmacists, Brussels, Belgium; Stephanie.Kohl{at}eahp.eu

https://doi.org/10.1136/ejhpharm-2022-003571

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In mid-September, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) issued a joint statement confirming that biosimilar medicines approved in the European Union are interchangeable with their reference medicine or with an equivalent biosimilar. This joint statement brings more clarity for healthcare professionals and consequently will improve patients’ access to biological medicines across the EU.

    Since 2006, EMA has been …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.